Cargando…

Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility

BACKGROUND: Patients with moderate to severe rheumatoid arthritis (RA) can be treated with a range of targeted therapies following inadequate response to conventional synthetic disease-modifying antirheumatic drugs such as methotrexate. Whereas clinical practice guidelines provide no formal recommen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnell, Christopher, Bergman, Martin, Basu, Dhiman, Kenney, James T, Withers, Johanna B, Logan, Jennifer, Harashima, Jeraldine Lim, Connolly-Strong, Erin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394192/ https://www.ncbi.nlm.nih.gov/pubmed/34669487 http://dx.doi.org/10.18553/jmcp.2021.21120

Ejemplares similares

Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
por: Cohen, Stanley, et al.
Publicado: (2021)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2020)

Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines
por: Johansen Taber, Katherine, et al.
Publicado: (2019)

Classifying Integrated Signature Molecules in Macrophages of Rheumatoid Arthritis, Osteoarthritis, and Periodontal Disease: An Omics-Based Study
por: Sao, Prachi, et al.
Publicado: (2022)

A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
por: Cohen, Stanley, et al.
Publicado: (2021)

The challenges in classifying rheumatoid arthritis-associated interstitial lung disease
por: Nurmi, Hanna, et al.
Publicado: (2020)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

An Integrated Glycosylation Signature of Rheumatoid Arthritis
por: Mayboroda, Oleg A., et al.
Publicado: (2023)

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
por: Sacristán, José A., et al.
Publicado: (2019)

Monocyte-specific gene signatures in rheumatoid arthritis
por: Grützkau, A, et al.
Publicado: (2004)

Functional Analysis of Autoantibody Signatures in Rheumatoid Arthritis
por: Milchram, Lisa, et al.
Publicado: (2022)

Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis
por: Withers, Mellissa H., et al.
Publicado: (2017)

Predictors of fatigue in rheumatoid arthritis
por: Druce, Katie L, et al.
Publicado: (2019)

Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland
por: Kelleher, Dan, et al.
Publicado: (2020)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Utilizing Regulatory T Cells Against Rheumatoid Arthritis
por: Haque, Mohammad, et al.
Publicado: (2014)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Molecular Characterization of Circulating Microbiome Signatures in Rheumatoid Arthritis
por: Hammad, Dargham B. M., et al.
Publicado: (2020)

Oral Microbial Signature of Rheumatoid Arthritis in Female Patients
por: Kozhakhmetov, Samat, et al.
Publicado: (2023)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
por: Kittiratchakool, Nitichen, et al.
Publicado: (2020)

Molecular signatures of rheumatoid arthritis characterized by transcriptome and proteome analysis
por: Glocker, MO, et al.
Publicado: (2005)

An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype
por: Whitaker, John W, et al.
Publicado: (2013)

Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis
por: Bienkowska, Jadwiga, et al.
Publicado: (2014)

Serum miRNA Signature in Rheumatoid Arthritis and “At-Risk Individuals”
por: Cunningham, Clare C., et al.
Publicado: (2021)

Molecular signature of methotrexate response among rheumatoid arthritis patients
por: Brynedal, Boel, et al.
Publicado: (2023)

Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease
por: Qin, Yan, et al.
Publicado: (2022)

Budget 1969 - Utilization of Unspent Personnel Money
Publicado: (1969)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Validation of rheumatoid arthritis diagnoses in health care utilization data
por: Kim, Seo Young, et al.
Publicado: (2011)

Utility of different cardiovascular disease prediction models in rheumatoid arthritis
por: Purcarea, A, et al.
Publicado: (2014)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
por: Kawalec, Paweł, et al.
Publicado: (2017)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Screening of gene signatures for rheumatoid arthritis and osteoarthritis based on bioinformatics analysis
por: He, Peiheng, et al.
Publicado: (2016)

A Four-miRNA-Based Diagnostic Signature for Rheumatoid Arthritis
por: Jiang, Xu, et al.
Publicado: (2022)

Initial presentation of early rheumatoid arthritis
por: Weman, Lauri, et al.
Publicado: (2023)

Machine Learning Applied to Patient‐Reported Outcomes to Classify Physician‐Derived Measures of Rheumatoid Arthritis Disease Activity
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

“Striving for a Good Life” – The Management of Rheumatoid Arthritis as Experienced by Patients
por: Bergsten, Ulrika, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_b4tio1k075bgfggnm5mou10rbq